- Home
- ELVN vs INVA Comparison
ELVN vs INVA Comparison
Compare ELVN & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVN | INVA |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ELVN | INVA |
|---|---|---|
| Price | $27.63 | $22.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $41.00 | $36.50 |
| AVG Volume (30 Days) | ★ 648.5K | 616.7K |
| Earning Date | 06-05-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.17 | ★ 816.67 |
| EPS | N/A | ★ 3.30 |
| Revenue | N/A | ★ $217,217,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $40.06 | $11.99 |
| P/E Ratio | ★ N/A | $6.72 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $13.30 | $16.52 |
| 52 Week High | $30.98 | $25.15 |
Technical Indicators
Market Signals| Indicator | ELVN | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 48.09 | 51.06 |
| Support Level | $18.89 | $19.16 |
| Resistance Level | $29.63 | $22.76 |
| Average True Range (ATR) | 1.56 | 0.62 |
| MACD | -0.38 | -0.17 |
| Stochastic Oscillator | 11.69 | 18.65 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.